文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

基于弥散性血管内凝血诊断标准的脓毒症相关凝血病治疗:一项前瞻性多中心观察性研究的事后分析

Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria: a post-hoc analysis of a prospective multicenter observational study.
PubMed 文献 · J Intensive Care · 2023-03-05
一句话结论脓毒症相关DIC患者中,DIC评分≥5且PT-INR≥1.5者接受抗凝血酶、重组人血栓调节蛋白或两者联合治疗与更好生存相关。

该研究为一项前瞻性多中心观察性研究的事后分析,纳入日本59个ICU的1178例成人严重脓毒症患者(2016年1月至2017年3月),最终分析1013例。采用多变量回归模型(含DIC评分与PT-INR的乘积项)及含三重交互项(抗凝治疗×DIC评分×PT-INR)的非线性限制性立方样条Cox比例风险回归分析。结果显示,PT-INR<1.5范围内,PT-INR升高与器官功能障碍和院内死亡恶化相关,且DIC评分越高该趋势越明显;抗凝治疗(抗凝血酶、重组人血栓调节蛋白或两者联合)在高DIC评分且高PT-INR患者中与更好生存结局相关。研究确定DIC评分≥5且PT-INR≥1.5作为筛选抗凝治疗最佳目标的临床阈值。

要点

  • 在严重脓毒症患者中,DIC评分≥5且PT-INR≥1.5者接受抗凝治疗(抗凝血酶、重组人血栓调节蛋白或联合)与更好生存结局相关。
  • PT-INR在<1.5范围内升高时,器官功能障碍和院内死亡随之恶化,DIC评分越高该趋势越明显。
  • 抗凝治疗定义为抗凝血酶、重组人血栓调节蛋白或两者联合使用。
  • 该研究为前瞻性多中心观察性研究的事后分析,结果可为抗凝治疗随机对照试验的设计提供参考。

适用人群与场景

  • 日本59个ICU的成人严重脓毒症患者,研究期间为2016年1月至2017年3月。
  • 最终分析1013例(自1178例严重脓毒症患者中纳入分析)。

诊断标准与关键阈值

  • DIC评分≥5且PT-INR≥1.5被确定为筛选抗凝治疗最佳目标的临床阈值。

处置流程与药物剂量

  • 抗凝治疗定义为给予抗凝血酶、重组人血栓调节蛋白或两者联合。

研究设计与关键结果

  • 研究类型为前瞻性多中心观察性研究的事后分析,纳入1178例成人严重脓毒症患者,最终分析1013例。
  • 回归模型显示,PT-INR在<1.5范围内升高时器官功能障碍和院内死亡恶化,且DIC评分越高该趋势越明显。
  • 三重交互分析显示,抗凝治疗在高DIC评分且高PT-INR患者中与更好生存结局相关。
  • 确定DIC评分≥5且PT-INR≥1.5为抗凝治疗最佳目标的临床阈值。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性研究的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,联合使用DIC评分和PT-INR有助于选择脓毒症诱导DIC中抗凝治疗的最佳患者人群。
  • 作者认为,本研究结果将为考察抗凝治疗对脓毒症效果的随机对照试验设计提供有价值的信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The development of disseminated intravascular coagulation (DIC) in patients with sepsis has been repeatedly confirmed as a factor associated with poor prognosis. Anticoagulant therapy has been expected to improve sepsis patient outcomes, whereas no randomized controlled trials have demonstrated the survival benefit of anticoagulant therapies in non-specific overall sepsis. Patient selection based on the component of "high disease severity" in addition to "sepsis with DIC" has recently proved important in identifying appropriate targets for anticoagulant therapy. The aims of this study were to characterize "severe" sepsis DIC patients and to identify the patient population benefiting from anticoagulant therapy.

METHODS: This retrospective sub-analysis of a prospective multicenter study included 1,178 adult patients with severe sepsis from 59 intensive care units in Japan from January 2016 to March 2017. We examined the association of patient outcomes, including organ dysfunction and in-hospital mortality, with the DIC score and prothrombin time-international normalized ratio (PT-INR), one of the components of the DIC score, using multivariable regression models including the cross-product term between these indicators. Multivariate Cox proportional hazard regression analysis with non-linear restricted cubic spline including a three-way interaction term (anticoagulant therapy × the DIC score × PT-INR) was also performed. Anticoagulant therapy was defined as the administration of antithrombin, recombinant human thrombomodulin, or their combination.

RESULTS: In total, we analyzed 1013 patients. The regression model showed that organ dysfunction and in-hospital mortality deteriorated with higher PT-INR values in the range of < 1.5 and that this trend was more pronounced with higher DIC scores. Three-way interaction analysis demonstrated that anticoagulant therapy was associated with better survival outcome in patients with a high DIC score and high PT-INR. Furthermore, we identified a DIC score ≥ 5 and PT-INR ≥ 1.5 as the clinical threshold for identification of optimal targets for anticoagulant therapy.

CONCLUSIONS: The combined use of the DIC score and PT-INR helps in selecting the optimal patient population for anticoagulant therapy in sepsis-induced DIC. The results obtained from this study will provide valuable information regarding the study design of randomized controlled trials examining the effects of anticoagulant therapy for sepsis.

TRIAL REGISTRATION: UMIN-CTR, UMIN000019742. Registered on November 16, 2015.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Wada T, Yamakawa K, Kabata D, et al. Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria: a post-hoc analysis of a prospective multicenter observational study. J Intensive Care. 2023. PMID: 36872342. doi:10.1186/s40560-023-00656-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。